Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-07-16 am EDT			5-day change	1st Jan Change
6,013 ^JPY	+0.43%		+2.31%	+55.29%

Jul. 10	Daiichi Sankyo Opens New Affiliate for Oncology in Greece	CI
Jul. 02	Financials lift Japanese shares on rate-hike speculation	RE

Daiichi Sankyo Company, Limited Provides Revenue Guidance for the Year Ending March 31, 2023

January 09, 2023 at 11:15 am EST

Daiichi Sankyo Company, Limited provided revenue guidance for the year ending March 31, 2023. The company expected revenue of JPY 1.25 trillion for the current fiscal year ending March 31, 2023.

Latest news about Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Opens New Affiliate for Oncology in Greece	Jul. 10	CI
Financials lift Japanese shares on rate-hike speculation	Jul. 01	RE
Daiichi Sankyo Buys Back 13.5 Billion Yen Worth of Shares in June	Jul. 01	MT
Sanofi eyes German insulin investment of up to $1.6 bln, source says	Jul. 01	RE
Daiichi Sankyo Buys Back Shares	Jul. 01	MT
Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2024.	Jun. 30	CI
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	Jun. 27	DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	Jun. 27	RE
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	Jun. 26	CI
Health Care Down as Moderna Slides -- Health Care Roundup	Jun. 26	DJ
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients	Jun. 19	MT
Daiichi Sankyo to Dispose of 320 Million Yen Worth of Shares as Restricted Shares Remuneration	Jun. 17	MT
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May	Jun. 03	MT
Transcript : Daiichi Sankyo Company, Limited - Special Call	Jun. 03
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	Jun. 03	MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	Jun. 03	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results	Jun. 02	RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels	Jun. 02	RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	Jun. 02	RE
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial	Jun. 02	CI
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population	Jun. 02	CI
RevolKa Signs Master Service Agreement with Daiichi Sankyo	May. 27	CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	May. 27	DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	May. 27	MT
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival	May. 27	MT

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5,987 JPY

Average target price

6,299 JPY

Spread / Average Target

+5.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+55.29%	72.41B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.42%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+14.19%	244B
ROCHE HOLDING AG	+5.81%	234B
NOVARTIS AG	+16.77%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Daiichi Sankyo Company, Limited Provides Revenue Guidance for the Year Ending March 31, 2023

Latest news about Daiichi Sankyo Co., Ltd.

Chart Daiichi Sankyo Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Daiichi Sankyo Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals